In addition to the anti-tumor cell-based secreted gp96-Ig vaccine approach, which was successfully used in Phase 1b/2 clinical trial against non-small cell lung cancer (NSCLC) (NCT02439450 [71]), we have also generated an anti-infectious cell-based secreted gp96-Ig vaccine approach [37] (Figure 1). The gene discussed is HSP90B1; the disease is non-small cell lung carcinoma.